

# Summary Report 2022



Boehringer  
Ingelheim

# Financial Highlights

Amounts in  
million EUR,  
unless otherwise  
indicated

	2022	2021	Change
Net sales	24,149	20,618	+ 17 %
Research and development	5,047	4,127	+ 22 %
Personnel expenses	6,620	5,692	+ 16 %
Average number of employees	53,155	52,391	+ 1 %
Operating income	4,770	4,705	+ 1 %
– as % of net sales	19.8	22.8	
Group profit	3,181	3,406	– 7 %
– as % of net sales	13.2	16.5	
Group equity	19,185	19,331	– 1 %
Equity ratio	45 %	48 %	
Investments in tangible assets	1,021	968	+ 5 %
Depreciation of tangible assets	693	609	+ 14 %

**Net sales by region (in million EUR)**

	2022	2021	Change
Americas	11,470	9,147	+ 25.4 %
Europe	7,543	6,554	+ 15.1 %
Asia / Australia / Africa (AAA)	5,136	4,917	+ 4.5 %

**Net sales by business (in million EUR)**

	2022	2021	Change
Human Pharma	18,461	15,294	+ 20.7 %
Animal Health	4,559	4,295	+ 6.1 %
Biopharmaceutical Contract Manufacturing	1,024	917	+ 11.7 %
Other sales	105	112	− 6.3 %

# Our Company

Boehringer Ingelheim is working on break-through therapies that transform lives, today and for generations to come. The research-driven biopharmaceutical company focuses on diseases for which no satisfactory treatment option exists to date. In Animal Health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry's top 20 companies. More than 53,000 employees create value through innovation daily for the three business areas Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

## Average number of employees by region

	2022	2021	Change
Americas	13,248	13,187	+0.5 %
Europe	29,221	28,266	+3.4 %
Asia / Australia / Africa (AAA)	10,686	10,938	-2.3 %
	53,155	52,391	+1.5 %

Human Pharma

18,461 million EUR (+ 20.7 %)

Top 4 products

Net sales (in million EUR)

	2022	Change
JARDIANCE® family	5,832	+ 48.0 %
OFEV®	3,227	+ 29.5 %
TRAJENTA® / JENTADUETO®	1,703	+ 9.7 %
SPIRIVA®	1,560	+ 0.8 %

# Animal Health

## 4,559 million EUR (+6.1 %)

### Top 4 products

#### Net sales (in million EUR)


	2022	Change
NEXGARD®	1,064	+16.2%
FRONTLINE®	401	-4.1%
HEARTGARD®	323	+5.2%
INGELVAC CIRCOFLEX® / FLEXCOMBO®	236	-6.7%



## Americas

**11,470 million EUR (+25.4%)**


The Americas region remained the company's most important sales market with a 47.5% share of total sales. The USA is the most important market with sales of 9,476 million EUR.



# Europe

**7,543 million EUR (+ 15.1 %)**

The Europe region accounted for 31.2 % of total sales. Germany is the most important market with sales of 2,092 million EUR.



## **Asia/Australia/ Africa (AAA)**

**5,136 million EUR (+4.5%)**

The AAA region's share of total sales was 21.3%. Japan is the most important market with sales of 1,454 million EUR.

# Research and Development

Boehringer Ingelheim's focus is on the research and development of innovative medicines and therapies for humans and animals. Innovation is thus decisive for the future of the company.

Boehringer Ingelheim operates major R&D centers for Human Pharma in, among other places, Germany (Biberach), the USA (Ridgefield), and Austria (Vienna), and 17 R&D sites for Animal Health in Europe, Asia, and America.

The company supplements its own broad R&D portfolio with partnerships involving academic institutions, biotech companies, and public research institutions around the world.

## Research and development

	2022	2021
Expenses in million EUR	5,047	4,127
– as % of net sales	20.9	20.0
Human Pharma expenses in million EUR	4,583	3,710
– as % of Human Pharma net sales	24.8	24.3
Animal Health expenses in million EUR	464	416
– as % of Animal Health net sales	10.2	9.7
Average number of employees	10,691	10,109
Investments in tangible assets in million EUR (without investments in infrastructure)	298	242

**If you have any queries or comments, please contact us.**

**C.H. Boehringer Sohn AG & Co. KG**

Binger Strasse 173

55216 Ingelheim

Germany

Telephone + 49 6132 77-0

Fax + 49 6132 72-0

**Contact**

Corporate Affairs

Matthias Reinig

[press@boehringer-ingelheim.com](mailto:press@boehringer-ingelheim.com)

[boehringer-ingelheim.com](http://boehringer-ingelheim.com)

**Issued by**

C.H. Boehringer Sohn AG & Co. KG

**Concept, design, and layout**

3st kommunikation GmbH, Mainz

[www.3st.de](http://www.3st.de)

**Copyright**

© C.H. Boehringer Sohn AG & Co. KG, 2023

All rights reserved. No part of this Annual Report 2022 may be reproduced or transmitted in any form or by any means, electronic or photocopy, without permission in writing from C.H. Boehringer Sohn AG & Co. KG. Figures from third parties used in the annual report are based on data available at the time the financial statement was drawn up.